Nitric oxide donor-based FFA1 agonists: Design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents

作者：Li, Zheng^*; Xu, Xue; Liu, Roujia; Deng, Fengjian; Zeng, Xiaohua; Zhang, Luyong^*

来源：Bioorganic & Medicinal Chemistry, 2018, 26(15): 4560-4566.

DOI：10.1016/j.bmc.2018.07.050

• Cardiovascular complications
• Diabetes
• FFA1
• Hybrid
• NO donor

The cardiovascular complications were highly prevalent in type 2 diabetes mellitus (T2DM), even at the early stage of T2DM or the state of intensive glycemic control. Thus, there is an urgent need for the intervention of cardiovascular complications in T2DM. Herein, the new hybrids of FFA1 agonist and NO donor were design to obtain dual effects of anti-hyperglycemic and anti-thrombosis. As expected, the induced-fit docking study suggested that it is feasible for our design strategy to hybrid NO donor with compound 1. These hybrids exhibited moderate FFA1 agonistic activities and anti-platelet aggregation activities, and their anti-platelet effects mediated by NO were also confirmed in the presence of NO scavenger. Moreover, compound 3 revealed significantly hypoglycemic effect and even stronger than that of TAK-875 during an oral glucose tolerance test in mice. Potent and multifunctional hybrid, such as compound 3, is expected as a potential candidate with additional cardiovascular benefits for the treatment of T2DM.

• 出版日期2018-8-15
• 单位中国药科大学; 广东药科大学